サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1519698

がん免疫療法市場レポート：治療タイプ、用途、エンドユーザー、地域別、2024年～2032年

Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 143 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
がん免疫療法市場レポート：治療タイプ、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん免疫療法の市場規模は2023年に1,189億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに2,610億米ドルに達し、2024年から2032年の間に8.92％の成長率（CAGR）を示すと予測しています。がん患者数の増加、政府の積極的な取り組み、医療保険の幅広い利用可能性などが市場を牽引する主な要因となっています。

世界のがん免疫療法市場分析：

主な市場促進要因：バランスの悪い食事や有害物質の摂取を原因とするがん患者の増加は、市場の成長を促す主な要因の1つです。これに加えて、世界中の大衆の間で様々ながん治療の選択肢に対する認識が高まっていることも市場成長に寄与しています。

主な市場動向：医療保険が広く普及し、簡単に利用できるようになったことと、ヘルスケア支出の増加が、業界の投資家に有利な成長機会を提供しています。これに加えて、免疫療法のような副作用の少ない先進的な治療法への嗜好が高まっていることも、市場に明るい展望をもたらしています。

地域情勢別：地域レベルでは、市場は北米、アジア太平洋、欧州、ラテンアメリカ、中東・アフリカに分類され、現在は北米が世界市場を独占しています。

競合情勢：世界のがん免疫療法市場における主要企業には、Amgen Inc.、AstraZeneca plc、Bayer AG、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche AG、GSK plc、Johnson &Johnson、Merck KGaA、Novartis AG、Pfizer Inc.、Sanofi S.A.、Seagen Inc.などがあります。

課題と機会：腫瘍の種類によって反応は異なります。しかし、特に低温の腫瘍では免疫療法が奏効しない場合があり、これは抵抗性の存在を示唆しています。従って、内在性または後天性の抵抗性の開拓は、免疫療法分野の市場参入者にとって大きな課題であると同時に重要な機会でもあります。

世界のがん免疫療法市場動向

がんの有病率の増加

世界中でがん患者数が増加していることが、がん免疫療法市場を牽引しています。国際がん研究機関（IARC）の推計によると、2020年のがん患者数は約1,929万人です。これらの症例は、2030年までに2,458万症例まで増加すると予測されています。このようながん患者の大幅な増加が、免疫療法のような効果的な治療ソリューションの需要を増大させています。GLOBOCANによると、2020年には米国だけで新たにがんと診断された症例は約228万1,658例、がんによる死亡は61万2,390例に上ります。これに加え、肺がんと乳がんは、個人の間で最もよく見られるがんの2つです。カナダがん協会（CCS）は、2020年には約2万9,800人のカナダ人が肺がんと診断され、新たながん患者の13％を占めると述べた。約21,200人のカナダ人が肺がんで死亡すると予想され、これは2020年のがん死亡者全体の25％を占める。このことは、効果的でより高度ながん免疫療法の必要性が高まっていることを示しています。このように、効果的かつ持続的ながん治療に対する需要の高まりは、市場全体に有利な成長機会をもたらすと予想されます。

新規免疫療法の承認の高まり

さまざまな新興国市場の主なプレーヤーは、より効果的で先進的な免疫療法を開発・導入するため、研究開発活動に積極的に投資しています。National Clinical Trials（NCT）Registryによると、2020年9月8日現在、免疫療法を用いたがん治療の開発のために世界中で1,000件以上の臨床試験が進行中です。さらに、各国の政府当局や関係規制当局は、新規免疫療法の承認プロセスを迅速化するためのイニシアチブをとっており、これが市場の成長をさらに促進すると予想されています。例えば、American Association for Cancer Researchが発表した記事によると、2023年7月、FDAはキザルチニブ（Vanflyta）を新たに診断された急性骨髄性白血病（AML）の異なる病期の治療薬として承認しました。キザルチニブは、AML症例の約3分の1でねじれるキナーゼであるFLT3に焦点を当てています。同様に2021年5月、米国FDAはアムジェンのルマクラス（ソトラシブ）を、変異を伴う局所進行性または転移性非小細胞肺がん（NSCLC）KRAS G12C患者の治療薬として承認しました。ルマクラスはNSCLCに対する最初で唯一の標的治療薬です。このような開発により、今後数年間はがん免疫療法市場の成長が促進されると予想されます。

製薬企業と研究機関のパートナーシップとコラボレーション

新製品を上市するために、大手企業によるさまざまな戦略的取り組みが行われており、市場全体に明るい見通しをもたらしています。例えば、2023年9月、Immatics社とModerna社は、オンコロジー治療薬を開発するために戦略的に提携しました。この提携には、イマティクスの治験薬PRAME203 TCRTとModernaが開発中のMARTE mRNAがんワクチンとの併用評価が含まれます。さらに、2023年8月、FBD Biologics LimitedとShanghai Henlius Biotech, Inc.は、新規免疫療法の開発を促進するための戦略的提携を締結しました。同様に、2023年12月、ドイツの研究機関であるBioMed Xは、日本の製薬会社である小野薬品工業株式会社との新たな共同研究プロジェクトを発表しました。同様に2023年12月、ドイツの研究機関BioMed Xは、日本の製薬会社である小野薬品工業株式会社と、好中球の抗腫瘍効果を活用した次世代免疫療法をデザインするための新たな共同研究プロジェクトを発表しました。アムジェン社、アストラゼネカ社、バイエル社、イーライリリー社など、いくつかの市場プレーヤーがM&A活動に関与しています。M&A活動を通じて、これらの企業は地理的範囲を拡大し、新しい領域に参入しています。その結果、予測期間中にがん免疫療法市場の収益が増加すると予測されます。

本レポートで扱う主な質問

  • 世界のがん免疫療法市場の市場規模は？
  • 2024-2032年における世界のがん免疫療法市場の予想成長率は？
  • 世界のがん免疫療法市場を牽引する主な要因は？
  • 世界のがん免疫療法市場に対するCOVID-19の影響は？
  • 世界のがん免疫療法市場の治療タイプ別内訳は？
  • 世界のがん免疫療法市場の用途別内訳は？
  • 世界のがん免疫療法市場の最大地域は？
  • 世界のがん免疫療法市場の主要プレーヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のがん免疫療法市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • モノクローナル抗体
    • 市場動向
    • 市場予測
  • がんワクチン
    • 市場動向
    • 市場予測
  • チェックポイント阻害剤
    • 市場動向
    • 市場予測
  • 免疫調節薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 肺がん
    • 市場動向
    • 市場予測
  • 乳がん
    • 市場動向
    • 市場予測
  • 大腸がん
    • 市場動向
    • 市場予測
  • 悪性黒色腫
    • 市場動向
    • 市場予測
  • 前立腺がん
    • 市場動向
    • 市場予測
  • 頭頸部がん
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • がん研究センター
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
    • Seagen Inc.
図表

List of Figures

  • Figure 1: Global: Cancer Immunotherapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Immunotherapy Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cancer Immunotherapy Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Cancer Immunotherapy Market: Breakup by Therapy Type (in %), 2023
  • Figure 5: Global: Cancer Immunotherapy Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cancer Immunotherapy Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Cancer Immunotherapy Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Cancer Immunotherapy (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Cancer Immunotherapy (Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Cancer Immunotherapy (Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Cancer Immunotherapy (Checkpoint Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Cancer Immunotherapy (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Cancer Immunotherapy (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Cancer Immunotherapy (Other Therapy Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Cancer Immunotherapy (Other Therapy Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Cancer Immunotherapy (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Cancer Immunotherapy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Cancer Immunotherapy (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Cancer Immunotherapy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Cancer Immunotherapy (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Cancer Immunotherapy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Cancer Immunotherapy (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Cancer Immunotherapy (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Cancer Immunotherapy (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Cancer Immunotherapy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Cancer Immunotherapy (Head and Neck Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Cancer Immunotherapy (Head and Neck Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Cancer Immunotherapy (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Cancer Immunotherapy (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Cancer Immunotherapy (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Cancer Immunotherapy (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Cancer Immunotherapy (Cancer Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Cancer Immunotherapy (Cancer Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Cancer Immunotherapy (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Cancer Immunotherapy (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Cancer Immunotherapy (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Cancer Immunotherapy (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: North America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: North America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United States: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United States: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Canada: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Canada: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Asia-Pacific: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Asia-Pacific: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: China: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: China: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Japan: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Japan: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: India: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: India: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: South Korea: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: South Korea: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Australia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Australia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Indonesia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Indonesia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Europe: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Europe: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Germany: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Germany: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: France: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: France: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: United Kingdom: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: United Kingdom: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Italy: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Italy: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Spain: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Spain: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Russia: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Russia: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Latin America: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Latin America: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Brazil: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Brazil: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Mexico: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Mexico: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Others: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Others: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Middle East and Africa: Cancer Immunotherapy Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Middle East and Africa: Cancer Immunotherapy Market: Breakup by Country (in %), 2023
  • Figure 88: Middle East and Africa: Cancer Immunotherapy Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Global: Cancer Immunotherapy Industry: SWOT Analysis
  • Figure 90: Global: Cancer Immunotherapy Industry: Value Chain Analysis
  • Figure 91: Global: Cancer Immunotherapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Immunotherapy Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cancer Immunotherapy Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
  • Table 3: Global: Cancer Immunotherapy Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Cancer Immunotherapy Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Cancer Immunotherapy Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cancer Immunotherapy Market: Competitive Structure
  • Table 7: Global: Cancer Immunotherapy Market: Key Players
目次
Product Code: SR112024A5095

The global cancer immunotherapy market size reached US$ 118.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 261.0 Billion by 2032, exhibiting a growth rate (CAGR) of 8.92% during 2024-2032. The growing number of cancer cases, favorable government initiatives, and wide availability of medical insurance represent some of the key factors driving the market.

Global Cancer Immunotherapy Market Analysis:

Major Market Drivers: The increasing cases of cancer on account of a poor balanced diet and consumption of toxic substances is one of the primary factors driving the growth of the market. In addition to this, the growing awareness about various cancer treatment options among the masses across the world is also contributing to the market growth.

Key Market Trends: The wide availability and easy access to medical insurance, along with the increasing healthcare expenditures, is offering lucrative growth opportunities to industry investors. In addition to this, the emerging preference for advanced treatment solutions with fewer side effects, like immunotherapy, is creating a positive outlook for the market.

Geographical Landscape: On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Competitive Landscape: Some of the leading players in the global cancer immunotherapy market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among others.

Challenges and Opportunities: Different tumor types respond differently. However, in some cases, especially cold tumors immunotherapy is unresponsive, suggesting the presence of resistance. Hence, the development of intrinsic or acquired resistance is a big challenge as well as a significant opportunity for the market players in the immunotherapy field.

Global Cancer Immunotherapy Market Trends

Increasing Prevalence of Cancer

The rising number of cancer cases across the world is primarily driving the market for cancer immunotherapies. The International Agency for Research on Cancer (IARC) estimated that, in the year 2020, there were about 19.29 million cancer cases. These cases are projected to increase to 24.58 million cases by 2030. Such a substantial growth in cancer cases is augmenting the demand for effective treatment solutions like immunotherapies. According to GLOBOCAN, in 2020, there were approximately 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer alone in the United States. In addition to this, lung cancer and breast cancer are two of the most common cancers found among individuals. The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer immunotherapy. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.

Rising Approval of Novel Immunotherapies

Various key market players are extensively investing in research and development activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, as of September 8, 2020, there were more than 1,000 ongoing clinical trials across the world for the development of cancer treatment with immune-based therapies. Moreover, government authorities and concerned regulators of numerous nations are taking initiatives to expedite the approval process of novel immunotherapies, which is anticipated to further catalyze the market growth. For instance, according to an article published by the American Association for Cancer Research, in July 2023, the FDA approved quizartinib (Vanflyta) for treating different phases of newly diagnosed acute myeloid leukemia (AML). Quizartinib focuses on FLT3, a kinase that goes twisted in about one-third of AML cases. Similarly, in May 2021, the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with KRAS G12C, which involves mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). LUMAKRAS is the first and only targeted treatment for NSCLC. Such developments are expected to propel the cancer immunotherapy market growth in the coming years.

Partnerships and Collaborations between Pharmaceuticals and Research Institutions

Various Strategic initiatives are being undertaken by major players to launch new products, which is creating a positive outlook for the overall market. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop Oncology Therapeutics. The collaboration includes an assessment of Immatics investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. Similarly, in December 2023, BioMed X, a German research institution, announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils. Several market players, such as Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are involved in merger and acquisition activities. Through M&A activity, these companies are expanding their geographic reach and entering new territories. This, in turn, is projected to bolster the cancer immunotherapy market revenue over the forecasted period.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy type, application and end user.

Breakup by Therapy Type:

Monoclonal Antibodies

Cancer Vaccines

Checkpoint Inhibitors

Immunomodulators

Others

Currently, monoclonal antibodies hold the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. According to the report, monoclonal antibodies represented the largest segment.

Increasing investment for research and development activities of monoclonal antibodies is opening new avenues for the growth of companies in the oncology therapeutics space. Monoclonal antibodies are extensively being studied for their therapeutic effects against various types of cancers. For instance, in August 2023, FDA approved Talvey to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of treatment, including proteasome inhibitors, immunomodulatory agents and an antiCD38 monoclonal antibody.

Breakup by Application:

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head and Neck Cancer

Others

Among these, lung cancer currently exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. According to the report, lung cancer accounted for the largest market share.

According to cancer immunotherapy market overview, the lung cancer segment accounted for the largest revenue share in the market. This can be attributed to the increasing prevalence of lung malignancies, the escalating adoption of immunotherapy, and the presence of a robust pipeline of investigational candidates. Furthermore, rising product approval and new product launches also providing a positive outlook to the market. For instance, in November 2023, the US Food and Drug Administration (FDA) granted marketing authorizations to Augtyro (Bristol, Inc.) for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC) with Repotrectinib.

Breakup by End User:

Hospitals

Cancer Research Centers

Clinics

Others

Hospitals account for the largest market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cancer research centers, clinics, and others. According to the report, hospitals accounted for the largest market share.

Growing cases of cancer, increasing treatment rates, along with a large number of hospitals offering immunotherapies are contributing to a rise in the number of patients admitted to a hospital. To treat cancer, hospitals are increasingly utilizing immunotherapies. According to an article published by the National Cancer Institute, in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.

Breakup by Regional:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America currently dominates the global market.

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for cancer immunotherapy.

The growth in the region can be attributed to the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives. According to GLOBOCAN, in the US, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the year 2020. Moreover, the presence of key players in this region is also contributing to the growth of the market. According to an article published by Elsevier Ltd., in April 2023, the US National Cancer Institute published its expected national cancer plan, a roadmap, and calls to action on improving all stages of care for those suffering from cancer.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Amgen Inc.

AstraZeneca plc

Bayer AG

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche AG

GSK plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi S.A

Seagen Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Cancer Immunotherapy Market Recent Developments

December 2023: Oxford University Hospitals launched a new mRNA cancer vaccine trial for patients with head and neck cancers.

December 2023: BioMed X, a German research institution announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.

July 2023: Spanish researchers at Cima University of Navarra developed a new immunotherapy combination for liver cancer. This therapy improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.

Key Questions Answered in This Report

  • 1. How big is the cancer immunotherapy market?
  • 2. What is the expected growth rate of the global cancer immunotherapy market during 2024-2032?
  • 3. What are the key factors driving the global cancer immunotherapy market?
  • 4. What has been the impact of COVID-19 on the global cancer immunotherapy market?
  • 5. What is the breakup of the global cancer immunotherapy market based on the therapy type?
  • 6. What is the breakup of the global cancer immunotherapy market based on the application?
  • 7. What is the breakup of the global cancer immunotherapy market based on end user?
  • 8. Which is the largest region in the cancer immunotherapy market?
  • 9. Who are the key players/companies in the global cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Immunotherapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Checkpoint Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Immunomodulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Breast Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Colorectal Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Melanoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Prostate Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Head and Neck Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cancer Research Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 SWOT Analysis
    • 14.3.7 GSK plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Johnson & Johnson
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck KGaA
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Sanofi S.A
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Seagen Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis